MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin (MacTEL-Supp)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by The Lowy Medical Research Institute Limited.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
The Lowy Medical Research Institute Limited
ClinicalTrials.gov Identifier:
NCT00568828
First received: December 5, 2007
Last updated: NA
Last verified: December 2007
History: No changes posted
  Purpose

Earlier investigations have detected low levels of macular pigment (MP) in the center of the fovea and a halo of MP at a higher eccentricity in persons with type 2 idiopathic juxtafoveal teleangiectasia (MACTEL)[Helb H-M, Charbel Issa P, Pauleikhoff D, Scholl HPN, Holz FG, MacTel-Study Group. Macular Pigment Density and Distribution in Patients with Macular Telangiectasia. ARVO Annual Meeting 2006, Fort Lauderdale, 30.04.-5.05.2006. Program # 5701/B795]. To date it is not known whether the total MP is reduced in MACTEL or whether even more MP accumulates at higher eccenticities compared to healthy probands. With the suggested study we aim to

  1. investigate Lutein and Zeaxanthin serum levels in MACTEL probands
  2. investigate and quantify MP at the posterior pole of MACTEL probands
  3. detect possible changes of MP concentration and distribution following supplementation with Lutein and Zeaxanthin

Condition
Macular Teleangiectasia
Macular Pigment

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pilot Study to Evaluate the Changes of Macular Pigment Optical Density in Patients With Idiopathic Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin

Resource links provided by NLM:


Further study details as provided by The Lowy Medical Research Institute Limited:

Primary Outcome Measures:
  • Macular Pigment Optical Density [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: December 2007
Estimated Study Completion Date: February 2008
  Hide Detailed Description

Detailed Description:

Rationale for performing this study Earlier investigations have detected low levels of macular pigment (MP) in the center of the fovea and a halo of MP at a higher eccentricity in persons with type 2 idiopathic juxtafoveal teleangiectasia (MACTEL)[Helb H-M, Charbel Issa P, Pauleikhoff D, Scholl HPN, Holz FG, MacTel-Study Group. Macular Pigment Density and Distribution in Patients with Macular Telangiectasia. ARVO Annual Meeting 2006, Fort Lauderdale, 30.04.-5.05.2006. Program # 5701/B795]. To date it is not known whether the total MP is reduced in MACTEL or whether even more MP accumulates at higher eccenticities compared to healthy probands. With the suggested study we aim to

  1. investigate Lutein and Zeaxanthin serum levels in MACTEL probands
  2. investigate and quantify MP at the posterior pole of MACTEL probands
  3. detect possible changes of MP concentration and distribution following supplementation with Lutein and Zeaxanthin

The suggested study During this study we plan to select at least 10 MACTEL probands with different patterns of MP distribution including

  1. those with detectable accumulation of MP in the center and segmental reduction of MP temporally
  2. those with nearly no central accumulation and and larger area of reduced MP temporally
  3. those with no detectable accumulation of MP in the center and a halo of MP at a more eccentric location These probands will be supplemented with Lutein (L) and Zeaxanthin (Z) (12mg L and 1 mg Z, provided as esters, 120mg Vitamin C, 17.6 mg Vitamin E, 10mg Zink, 40µg Selen (Ocuvite Lutein™)) for a duration of nine months. During the supplementation and three months after stop of supplementation, probands will be investigated every three months including

1. ophthalmologic investigation, 2. fundus photography, 3. measurement of MP with a modified Heidelberg retina Angiograph employing two excitation wavelengths (514 and 488nm) 4. measurement of L and Z in serum.

Aim of the study

  1. Investigation of changes of MP concentration and distribution following supplementation of L and Z in MACTEl probands
  2. How do serum levels of L and Z change in these probands?

Visit:

V1 Screening & Start of supplementat V2 V3 V4 End of supplemenation V5 after stop of intake Months 0 3 6 9 12 general Informed consent X Medical history X in- and exclusion criteria X concommitant medication X X X X X Adverse events X X X X Pill count X X X Vital signs/ BMI X X Slitlamp investigation X X X X X Fundusphotography X X Visual acuity X X X X X Supplementation X X X Measurement of Xanthophylls Eye: MPOD (HRA) X X X X X Food frequency questionnaire X X Blood collection For (Heparin) Plasma to quantify Xanthophylls and Lipids X X X X X

Probands resident within a perimeter of 40km around the clinic will be preferentially selected to lower travel expenses. Recruitment takles place during regular visits in the course of the MACTEL study. For the angiography a vein will be punctated so that no additional punction is needed. Serum ist centrifuged at 1500g for 15min and kept at -70°C until analyse. Analyse of the Xanthophylls and Lipids in serum will be performed at the central laboratory of the University of Münster.

Autofluorescence imaging is part of study protocol for MACTEL Study. Two main images will be taken, one with an excitation wavelength of 488nm (good absorption by MP) and one with 514nm (poor absorption by MP). The digital subtration of both images provides a map of MP density around the fovea.

Inclusion criteria Informed consent Age at least 18y.? Type 2 IMT? Healthy general condition? At least one eye free from lens- or retina problems interfering with MP measurement with the modofied Heidelberg retina angiograph? Exclusion criteria No informed consent ? Younger than als 18 y.? Intake of Supplements containing L and Z (> 3mg L und >1mg Z) during the last 6 months? Bad general condition/ unintended loss of weight (>10%) within the last 3 monhs?

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

12 patients with Macular Teleangiectasia

Criteria

Inclusion Criteria:

  • Different distribution of macular pigment in patients with known macular teleangiectasia

Exclusion Criteria:

  • No
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00568828

Contacts
Contact: Daniel Pauleikhoff, MD 49-251-933080 dapauleikhoff@muenster.de

Locations
Germany
Dep. of Ophthalmology, St. Franziskus Hospital Recruiting
Muenster, Germany, 48145
Contact: Meike Zeimer, MD    49-251-933080    kpl-auge@muenster.de   
Sponsors and Collaborators
The Lowy Medical Research Institute Limited
Investigators
Principal Investigator: Daniel Pauleikhoff, MD Chairman Dep. of Ophthalmology, St.Franziskus Hospital, Muenster, Germany
  More Information

No publications provided

Responsible Party: Daniel Pauleikhoff MD, Dep. of Ophthalmology, St. Franziskus Hospital, Muenster, Germany
ClinicalTrials.gov Identifier: NCT00568828     History of Changes
Other Study ID Numbers: MacTEL Supplement
Study First Received: December 5, 2007
Last Updated: December 5, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by The Lowy Medical Research Institute Limited:
Macular Teleangiectasia
Macular Pigment

ClinicalTrials.gov processed this record on April 15, 2014